Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016232 · ClinicalTrials.gov registry record · NA
Adaptive Intervention to Facilitate PrEP Uptake/Adherence Among Transgender Women
A NA study of Prevention, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 123
- Enrollment target
- 1
- Study location
NCT05016232: Completed NA study of Prevention, sponsored by University of California, Los Angeles.
NCT05016232 is a NA study of Prevention that has completed, run by University of California, Los Angeles. The registered enrollment target is 123 participants, below the 49,981-participant average among 11 other Prevention trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05016232, a NA study of Prevention, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 123 participants
- Enrollment target
- 1
- Study location
Study Summary
"PrEP N' Shine" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Transgender women (TGW).
Primary Outcome
Linkage to care and PrEP Initiation measured through verified medical appointment at PrEP Clinic and pharmacy through medical release.
Conditions Studied
Interventions
- BEHAVIORAL PrEP N' Shine: Strength Based Case Management (Stage 1)
- BEHAVIORAL PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)
Study Locations (1)
California
- UCLA Center for LGBTQ+ Advocacy, Research & Health - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
What the finished NCT05016232 record still lists
NCT05016232 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 49,981-participant average among 11 other Prevention trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Prevention appearing as the primary indexed condition, and to 2 interventions - of which PrEP N' Shine: Strength Based Case Management (Stage 1) is the first listed.
NCT05016232 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05016232 about?
NCT05016232 is a clinical study titled "Adaptive Intervention to Facilitate PrEP Uptake/Adherence Among Transgender Women". "PrEP N' Shine" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Transgender women (TGW).
What is the current status of trial NCT05016232?
This trial is currently completed. It is a NA study. The enrollment target is 123 participants. The study started on 2022-10-18. Estimated completion is 2024-06-30.
What conditions does trial NCT05016232 study?
This clinical trial studies the following conditions: Prevention.
What interventions are being tested in trial NCT05016232?
The interventions under investigation include: PrEP N' Shine: Strength Based Case Management (Stage 1) (BEHAVIORAL), PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05016232?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05016232 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05016232's enrollment target sits among peer trials
123 9th of 11 higher than 3 of 11 other Prevention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).
RECRUITING · NA
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Optimizing PrEP Uptake and Adherence Among Male Sex Workers
RECRUITING · NA
-
Enhancing Oral Cancer Awareness
RECRUITING · NA
-
Virtual Reality Experience for Stress Reduction in Cardiology Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI